Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Pharmacoeconomics
मुख्य लेखकों: Blommestein, Hedwig M., Armstrong, Nigel, Ryder, Steve, Deshpande, Sohan, Worthy, Gill, Noake, Caro, Riemsma, Rob, Kleijnen, Jos, Severens, Johan L., Al, Maiwenn J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer International Publishing 2015
विषय:
Review Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4706836/
https://ncbi.nlm.nih.gov/pubmed/26314282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0318-3
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन